Drug Development Strategy
Clinical development and lifecycle strategy from early phase through approval.
Biopharma Strategic Advisor & Consulting
Where clinical insight meets product development, medical affairs & commercialization strategy.
Strategic advisory and consulting for biopharma founders and life-sciences leaders — bridging clinical medicine, drug development, medical affairs, and commercialization.
20+ Years in clinical medicine & pharma
Global Drug development & medical affairs leadership
MD Yale · RWJ Medical School · Baylor · MIT
Houston, Texas Global advisor
Who is Ike Ogbaa, MD
Physician, biopharma executive, and trusted advisor.
Dr. Ike pairs frontline clinical experience with biopharma executive leadership across global pharma and emerging biotech — helping teams develop, launch, and commercialize therapies, build medical strategy, and grow with integrity.
From the bedside to the boardroom, he has led drug development and global medical affairs at companies including Immunovant, Bluebird Bio, and Chinook Therapeutics (Novartis), with earlier roles at GSK, Sanofi, Bayer, and Merck.
Read the full story → What I do
Advisory across the biopharma value chain
From medical affairs strategy to launch, leadership, and beyond.
Medical Affairs Strategy
Build and scale the medical affairs function for biotech and emerging pharma.
Drug Launch & Commercialization
Launch readiness and go-to-market strategy across therapeutic areas.
Rare Disease & Specialty
Commercialization strategy for rare and specialty therapeutics.
AI in Pharma Advisory
Apply AI to clinical trials, operations, and regulatory acceleration.
Global Health & Market Access
Emerging-market expansion and equitable access, including sub-Saharan Africa.
Executive & Physician Leadership
Leadership development for clinical and biopharma leaders.
The approach
Science-led. Patient-focused. Commercially sharp.
Great strategy lives at the intersection of rigorous science and real-world execution. Dr. Ogbaa brings both — translating complex clinical and regulatory realities into clear decisions that move therapies forward.
- Deep medical and scientific credibility
- Launch experience across multiple therapeutic areas
- A genuine commitment to access and health equity
A collaborative approach
From question to lasting impact
01
Discover
Clarify the challenge, stakeholders, and what success looks like.
02
Diagnose
Assess the science, strategy, and gaps with a clinical and commercial lens.
03
Design
Shape a clear, actionable plan tailored to your stage and goals.
04
Deliver
Advisory and execution support to drive momentum.
05
Sustain
Embed the strategy and measure real, lasting impact.
In his words
Perspectives from Dr. Ike
"This is an exciting time in pharma — groundbreaking science is transforming how we tackle serious disease. The work is balancing that innovation with real patient access."
Dr. Ike Ogbaa, MD
"AI holds real promise — in trial recruitment, operations, and regulatory speed — but only if we implement it in ways that minimize bias."
Dr. Ike Ogbaa, MD
"We have to broaden clinical trial participation in underrepresented regions, including sub-Saharan Africa, so research benefits everyone."
Dr. Ike Ogbaa, MD
Leadership experience across
ImmunovantBluebird BioChinook, a Novartis companyGSKSanofiBayerMerckLexicon
Ready to bring Dr. Ike into the room?
Whether you're preparing for launch, scaling medical affairs, or planning a keynote — let's start the conversation.